Taysha Gene Therapies slides after equity offering launch

Taysha Gene Therapies

26/06/2024 13:50

** Taysha Gene Therapies'  TSHA.O  shares down 10% premarket
at $2.22, a 2-mth low, as co looks to raise equity
    ** Co late Tues commenced up to $75 mln offering of stock
and pre-funded warrants
    ** It plans to use net proceeds to fund clinical, regulatory
and manufacturing development of TSHA-102, its treatment for
Rett syndrome
    ** Rett syndrome is a rare neurodevelopmental disorder with
no approved disease-modifying therapies
    ** Taysha has ~187 mln shares outstanding for ~$461 mln
market cap, and ~153.3 mln shares of public float, per LSEG
    ** Jefferies and Goldman leading the offering, along with
Cantor
    ** Through Tues, TSHA shares up 39% YTD. Shares closed at 60
cents a year ago

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))